Taysha Gene Therapies Announces $200M Offering

Announcement

Taysha Gene Therapies Inc (NASDAQ:TSHA) disclosed that it has commenced an underwritten public offering of its common stock together with pre‑funded warrants, targeting gross proceeds of $200 million. The securities will be issued directly by Taysha.

Offering Terms

The company granted the underwriters a 30‑day option to purchase up to an additional 15 percent of the shares being offered, which includes the shares underlying the pre‑funded warrants. The offering is subject to market conditions.

Underwriters

Jefferies, Goldman Sachs & Co. LLC, Piper Sandler and Cantor are acting as joint book‑running managers, while Baird is serving as the lead manager for the transaction.

Market Reaction

Following the announcement, Taysha’s shares fell 8.5 percent in after‑hours trading on Wednesday.